Cullinan Oncology LLC Cash Flow Conversion Efficiency
Cullinan Oncology LLC cash flow conversion efficiency. Based on the latest financial reports, Cullinan Oncology LLC (CGEM) has a cash flow conversion efficiency ratio of -0.126x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-46.05 Million) by net assets ($366.17 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Cullinan Oncology LLC (2013–2025)
Cash flow conversion efficiency of Cullinan Oncology LLC from 2013 to 2025. This chart illustrates how Cullinan Oncology LLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Cullinan Oncology LLC stock quote for real-time trading data and today's change.
Cullinan Oncology LLC Cash Flow Conversion Ratio Explained
Cullinan Oncology LLC cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Cullinan Oncology LLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cullinan Oncology LLC ranked by their cash flow conversion efficiency. Also see market value of Cullinan Oncology LLC for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
TOA Paint (Thailand) Public Company Limited
BK:TOA
|
0.054x |
|
GrocerIQ, Inc
NYSE:WPFHD
|
N/A |
|
Boai NKY Pharmaceuticals Ltd
SHE:300109
|
0.042x |
|
Dynamatic Technologies Limited
NSE:DYNAMATECH
|
0.068x |
|
Major Drilling Group International
TO:MDI
|
0.020x |
|
Quechen Silicon Chemical Co. Ltd.
SHG:605183
|
0.048x |
|
Sprinklr Inc
NYSE:CXM
|
0.144x |
|
Jiajiayue Group Co Ltd
SHG:603708
|
0.242x |
Annual Cash Flow Conversion Efficiency for Cullinan Oncology LLC (2013–2025)
The table below shows the annual cash flow conversion efficiency of Cullinan Oncology LLC from 2013 to 2025. Review CGEM free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $408.73 Million | $-175.75 Million | -0.430x | -74.69% |
| 2024-12-31 | $590.33 Million | $-145.30 Million | -0.246x | +16.80% |
| 2023-12-31 | $453.89 Million | $-134.28 Million | -0.296x | -24.96% |
| 2022-12-31 | $535.03 Million | $-126.66 Million | -0.237x | -131.86% |
| 2021-12-31 | $425.37 Million | $-43.43 Million | -0.102x | +31.30% |
| 2020-12-31 | $200.31 Million | $-29.77 Million | -0.149x | -128.38% |
| 2019-12-31 | $-39.91 Million | $-20.90 Million | 0.524x | -20.20% |
| 2018-12-31 | $-20.65 Million | $-13.55 Million | 0.656x | +64.77% |
| 2016-12-31 | $-574.85K | $-228.91K | 0.398x | +1962.80% |
| 2015-12-31 | $-1.24 Million | $-24.03K | 0.019x | -76.10% |
| 2014-12-31 | $-1.14 Million | $-91.72K | 0.081x | -88.70% |
| 2013-12-31 | $-1.00 Million | $-718.41K | 0.715x | -- |
About Cullinan Oncology LLC
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049,… Read more